After a median follow-up of 40 months , median progression-free survival ( according to independent radiologic review ) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group ( hazard ratio favoring the VR-CAP group , 0.63 ; P < 0.001 ) , a relative improvement of 59 % .